Open Access Platform
If you would like more information or are interested in working with ORDI, please contact us at: OxfordRareDiseases@medsci.ox.ac.uk
More information about the services that the Oxford Rare Disease Initiative offers.
Open access translational platform for rare diseases
Structural Genomics Consortium call for projects to facilitate drug discovery
With a community of more than 250 researchers working on over 350 rare diseases, and a network of pharmaceutical, biotechnology and VC partners, University of Oxford boasts a unique ecosystem and opportunity to transform rare disease research into the next-generation therapies, diagnostics and technologies to address the unmet need.
Cognizant that a main challenge in rare disease drug discovery, as with other therapeutic areas, lies in the lack of high quality tools, reagents and proof-of-concept data for target validation, the SGC has created a free-of-charge University-wide platform for collaborative opportunities, aimed at enabling research of the rare disease community. The SGC generates tools and reagents (structures, assays, small molecules) to facilitate early-stage drug discovery, via a number of funded programmes including the Target Enabling Package, chemical probes and ULTRA-DD.
We therefore seek disease-associated target areas, at various stages of development, from researchers across the University who would be interested in the collaboration. The anticipated outcomes of the collaboration, with the overall objectives of translating research into clinics, could include developing proof-of-therapeutic-concept data, identifying leveraged funding mechanisms, and establishing industrial partnerships.
As an expression of interest, please use the online nomination form with brief description of: research area, targets of interest and scientific questions to be addressed.
For further enquiries, please contact:
Wyatt Yue at the SGC: email@example.com